Looks like you’re on the UK site. Choose another location to see content specific to your location

Home Industry News Bayer HealthCare sees continued growth in Q2 2013

Bayer HealthCare sees continued growth in Q2 2013

2nd August 2013

Bayer HealthCare experienced a better-than-expected performance during the second quarter of 2013, according to data from Bayer's latest financial report.

The group's healthcare division generated sales of 4.8 billion euros (4.19 billion pounds) during the quarter, up by 3.8 percent year on year, with the company's pharmaceutical revenues surging by 5.5 percent thanks to strong demand for new offerings Xarelto, Eylea and Stivarga.

Bayer's management board chairman Dr Marijn Dekkers said: "The launches of new pharmaceutical products are progressing considerably better than expected."

Its consumer health segment grew by 1.4 percent, with all of its divisions seeing improved results, while the medical care and animal health businesses also experienced positive trends.

This contributed to a 10.36 billion euro quarterly sales total for the Bayer group as a whole, allowing the organisation to maintain its 2013 full-year growth targets.

Bayer HealthCare can expect to see further growth over the next few months after it recently agreed deals to acquire pharmacy supplier Steigerwald Arzneimittelwerk and birth control solutions specialist Conceptus.ADNFCR-8000103-ID-801620176-ADNFCR

We currently have 9 jobs available in Pharmacy industry, find your perfect one now.

Stay informed

Receive the latest industry news, Tips
and straight to your inbox.